10-QPeriod: Q1 FY2025

GE HealthCare Technologies Inc. Quarterly Report for Q1 Ended Mar 31, 2025

Filed April 30, 2025For Securities:GEHC

Summary

GE HealthCare Technologies Inc. (GEHC) reported a solid first quarter for 2025, with total revenues reaching $4.78 billion, a 3% increase year-over-year, and 4% on an organic basis. The company demonstrated strong profitability, with net income attributable to GE HealthCare rising 51% to $564 million, and diluted Earnings Per Share (EPS) increasing to $1.23 from $0.81 in the prior year. Key drivers of this performance include robust growth in the Pharmaceutical Diagnostics (PDx) segment and strong performance in the United States and Canada (USCAN). The company also benefited from a significant one-time gain from the remeasurement of its previously held 50% interest in Nihon Medi-Physics (NMP) as part of its acquisition. Despite some headwinds from unfavorable foreign currency impacts and ongoing challenges in the China market, GE HealthCare's operational execution and strategic acquisitions, like the full acquisition of NMP, are contributing positively to its financial results.

Financial Highlights

48 data points
Beta

Revenue

$4.78B

42.1% Gross Margin

Net Income

$564.00M

11.8% Net Margin

EPS (Diluted)

$1.23

Total Assets

$33.59B

Cash & Equivalents

$2.45B

Free Cash Flow

$250.00M

Financial Statements
Beta
Revenue$4.78B
Gross Profit$2.01B
R&D Expenses$344.00M
SG&A Expenses$1.04B
Operating Expenses$1.38B
Operating Income$629.00M
Net Income$564.00M
EPS (Basic)$1.23
EPS (Diluted)$1.23
Shares Outstanding (Basic)457.00M
Shares Outstanding (Diluted)459.00M

Key Highlights

  • 1Total revenues increased by 3% to $4.78 billion, with organic revenue growth of 4%.
  • 2Net income attributable to GE HealthCare surged 51% to $564 million, leading to a significant EPS increase to $1.23.
  • 3The acquisition of the remaining 50% of Nihon Medi-Physics (NMP) on March 31, 2025, resulted in a one-time gain of $97 million.
  • 4Segment performance was strong, with PDx showing 6% revenue growth and Imaging segment revenue up 4%.
  • 5The United States and Canada (USCAN) region showed robust revenue growth of 7%, driven by all segments.
  • 6Operating income increased by 17% to $629 million, with operating margin improving to 13.2% from 11.6%.
  • 7The company announced a new $1,000 million share repurchase program on April 30, 2025.

Frequently Asked Questions

The substantial increase in net income was driven by a combination of factors: a 17% increase in operating income due to improved gross profit and better cost management, a decrease in interest and other financial charges, and a significant one-time gain of $97 million from the remeasurement of GE HealthCare's existing 50% interest in Nihon Medi-Physics (NMP) as part of acquiring the remaining stake. Additionally, a decrease in the provision for income taxes, partly due to the release of foreign tax reserves, also contributed.

GE HealthCare completed the acquisition of the remaining 50% of Nihon Medi-Physics (NMP) on March 31, 2025. This transaction resulted in a one-time pre-tax gain of $97 million recognized in 'Other (income) expense – net' due to the remeasurement of the previously held 50% equity interest to its fair value. NMP is now fully integrated into the Pharmaceutical Diagnostics (PDx) segment.

The Pharmaceutical Diagnostics (PDx) segment showed strong revenue growth of 6%, while the Imaging segment grew by 4%. The Advanced Visualization Solutions (AVS) and Patient Care Solutions (PCS) segments saw more modest growth of 1% each. Regionally, the United States and Canada (USCAN) delivered a robust 7% revenue increase. EMEA was flat, while China experienced a slight 1% revenue decrease, and Rest of World saw a 2% decline, with some of these regional variations influenced by foreign currency impacts and specific market dynamics.

As of March 31, 2025, GE HealthCare's total debt stood at $8.76 billion, a decrease from $8.95 billion at the end of 2024, primarily due to a $250 million repayment of its Term Loan Facility. The company has access to substantial revolving credit facilities totaling $3.5 billion and maintains a healthy cash and cash equivalents balance of $2.47 billion. Management believes these resources are sufficient to meet operational needs for at least the next 12 months. Notably, the company announced a new $1,000 million share repurchase program authorized on April 30, 2025, indicating a commitment to returning capital to shareholders.